Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ocular Therapeutix (OCUL) Long-Term Debt Repayments: 2013-2021

Historic Long-Term Debt Repayments for Ocular Therapeutix (OCUL) over the last 1 years, with Jun 2021 value amounting to $2.1 million.

  • Ocular Therapeutix's Long-Term Debt Repayments was N/A to $2.1 million in Q2 2021 from the same period last year, while for Jun 2021 it was $7.3 million, marking a year-over-year change of. This contributed to the annual value of $26.1 million for FY2023, which is N/A change from last year.
  • As of Q2 2021, Ocular Therapeutix's Long-Term Debt Repayments stood at $2.1 million, which was up 0.05% from $2.1 million recorded in Q1 2021.
  • In the past 5 years, Ocular Therapeutix's Long-Term Debt Repayments ranged from a high of $2.1 million in Q2 2021 and a low of $1.0 million during Q1 2018.
  • For the 1-year period, Ocular Therapeutix's Long-Term Debt Repayments averaged around $2.1 million, with its median value being $2.1 million (2021).
  • Data for Ocular Therapeutix's Long-Term Debt Repayments shows a maximum YoY declined of 20.85% (in 2018) over the last 5 years.
  • Over the past 3 years, Ocular Therapeutix's Long-Term Debt Repayments (Quarterly) stood at $1.3 million in 2017, then declined by 20.85% to $1.5 million in 2018, then reached $2.1 million in 2021.
  • Its Long-Term Debt Repayments stands at $2.1 million for Q2 2021, versus $2.1 million for Q1 2021 and $1.5 million for Q4 2018.